Universal Beteiligungs und Servicegesellschaft mbH Has $4.75 Million Holdings in Apogee Therapeutics Inc. (NASDAQ:APGE)

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH reduced its stake in Apogee Therapeutics Inc. by 11.6%, now holding 127,208 shares valued at approximately $4.75 million.
• Institutional ownership is high, with 79.04% of Apogee Therapeutics shares held by hedge funds and other investors, while insiders own 42.77%.
• Apogee Therapeutics' stock opened at $40.82, down 2.0%, with a market cap of $1.88 billion and a consensus rating of "Buy" from analysts with an average price target of $99.00.

Universal Beteiligungs und Servicegesellschaft mbH trimmed its holdings in shares of Apogee Therapeutics Inc. (NASDAQ:APGE - Free Report) by 11.6% in the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 127,208 shares of the company's stock after selling 16,744 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH owned 0.28% of Apogee Therapeutics worth $4,752,000 as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. GF Fund Management CO. LTD. bought a new position in shares of Apogee Therapeutics during the 4th quarter worth approximately $43,000. Optimize Financial Inc bought a new position in shares of Apogee Therapeutics during the 4th quarter worth approximately $203,000. BNP Paribas Financial Markets bought a new position in shares of Apogee Therapeutics during the 4th quarter worth approximately $219,000. Commonwealth Equity Services LLC bought a new position in shares of Apogee Therapeutics during the 4th quarter worth approximately $222,000. Finally, KLP Kapitalforvaltning AS acquired a new stake in shares of Apogee Therapeutics in the 4th quarter valued at approximately $226,000. 79.04% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, insider Carl Dambkowski sold 10,090 shares of the company's stock in a transaction that occurred on Wednesday, July 2nd. The stock was sold at an average price of $45.09, for a total value of $454,958.10. Following the completion of the transaction, the insider owned 238,998 shares of the company's stock, valued at $10,776,419.82. This represents a 4.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders sold a total of 15,540 shares of company stock worth $653,093 over the last three months. 42.77% of the stock is currently owned by insiders.

Apogee Therapeutics Stock Performance

Shares of NASDAQ APGE traded up $0.61 during mid-day trading on Thursday, reaching $38.22. The company had a trading volume of 133,170 shares, compared to its average volume of 759,712. Apogee Therapeutics Inc. has a one year low of $26.20 and a one year high of $63.50. The firm has a market cap of $1.76 billion, a price-to-earnings ratio of -10.51 and a beta of 1.47. The business's 50-day simple moving average is $40.33 and its 200 day simple moving average is $38.11.

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last issued its earnings results on Monday, May 12th. The company reported ($0.95) EPS for the quarter, topping the consensus estimate of ($1.19) by $0.24. On average, sell-side analysts anticipate that Apogee Therapeutics Inc. will post -3.09 EPS for the current year.

Analysts Set New Price Targets

APGE has been the subject of several recent analyst reports. Citigroup reissued a "buy" rating on shares of Apogee Therapeutics in a report on Monday, July 7th. Wedbush reissued an "outperform" rating and issued a $90.00 price objective on shares of Apogee Therapeutics in a report on Monday, July 7th. Guggenheim reissued a "buy" rating and issued a $116.00 price objective on shares of Apogee Therapeutics in a report on Wednesday, July 2nd. Finally, BTIG Research increased their price objective on Apogee Therapeutics from $100.00 to $115.00 and gave the company a "buy" rating in a report on Monday, July 7th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $99.00.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.